Plasma Enalapril Levels and Hormonal Effects After Short- and Long-term Administration in Essential Hypertension

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1984 Jan 1

PMID 6099738

Citations 12

Authors

C I Johnston

B J Jackson

I Larmour

R Cubella

D Casley

Affiliations

Soon will be listed here.

Abstract

Enalapril lowers blood pressure both acutely and during long-term therapy in patients with essential hypertension. After a single 10 mg dose of enalapril a close relationship between plasma enalaprilic acid (MK-422) levels, angiotensin converting enzyme (ACE) inhibition and the acute hypotensive and hormonal effects was demonstrated. During long-term administration of enalapril, a similar relationship between the plasma enalaprilic acid level, ACE inhibition and the hypotensive effect was shown, although the dose-response curve for plasma enalaprilic acid to ACE inhibition was displaced to the right compared to the acute dose-response curve. Several weeks' administration of enalapril was needed to reach stable plateau levels of plasma enalaprilic acid and ACE inhibition. During long-term treatment with enalapril in essential hypertension, there was sustained inhibition of ACE and the associated hormonal changes.

Citing Articles

Clinically Relevant Doses of Enalapril Mitigate Multiple Organ Radiation Injury.

Cohen E, Fish B, Moulder J Radiat Res. 2016; 185(3):313-8.

PMID: 26934483 PMC: 4825861. DOI: 10.1667/RR4243.S1.

A detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone system.

Claassen K, Willmann S, Eissing T, Preusser T, Block M Front Physiol. 2013; 4:4.

PMID: 23404365 PMC: 3567458. DOI: 10.3389/fphys.2013.00004.

Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview.

MacFadyen R, MEREDITH P, Elliott H Clin Pharmacokinet. 1993; 25(4):274-82.

PMID: 8261712 DOI: 10.2165/00003088-199325040-00003.

Choosing the right ACE inhibitor. A guide to selection.

Leonetti G, Cuspidi C Drugs. 1995; 49(4):516-35.

PMID: 7789286 DOI: 10.2165/00003495-199549040-00003.

An overview of the clinical pharmacology of enalapril.

Davies R, Gomez H, Irvin J, Walker J Br J Clin Pharmacol. 1984; 18 Suppl 2:215S-229S.

PMID: 6099737 PMC: 1463484. DOI: 10.1111/j.1365-2125.1984.tb02601.x.

References

ONDETTI M, Rubin B, Cushman D . Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science. 1977; 196(4288):441-4. DOI: 10.1126/science.191908. View

Case D, Atlas S, LARAGH J, SEALEY J, Sullivan P, MCKINSTRY D . Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,225, captopril) in hypertensive patients. Prog Cardiovasc Dis. 1978; 21(3):195-206. DOI: 10.1016/0033-0620(78)90025-7. View

Johnston C, Millar J, McGrath B, Matthews P . Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension. Lancet. 1979; 2(8141):493-6. DOI: 10.1016/s0140-6736(79)91552-6. View

Brunner H, Gavras H, Waeber B, Textor S, Turini G, Wauters J . Clinical use of an orally acting converting enzyme inhibitor: captopril. Hypertension. 1980; 2(4):558-66. DOI: 10.1161/01.hyp.2.4.558. View

LARAGH J, Case D, Atlas S, SEALEY J . Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension. 1980; 2(4):586-93. DOI: 10.1161/01.hyp.2.4.586. View

PATCHETT A, Harris E, Tristram E, Wyvratt M, Wu M, Taub D . A new class of angiotensin-converting enzyme inhibitors. Nature. 1980; 288(5788):280-3. DOI: 10.1038/288280a0. View

Heel R, Brogden R, Speight T, Avery G . Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980; 20(6):409-52. DOI: 10.2165/00003495-198020060-00001. View

Biollaz J, Burnier M, Turini G, Brunner D, Porchet M, Gomez H . Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther. 1981; 29(5):665-70. DOI: 10.1038/clpt.1981.92. View

Millar J, McGrath B, Matthews P, Johnston C . Acute effects of captopril on blood pressure and circulating hormone levels in salt-replete and depleted normal subjects and essential hypertensive patients. Clin Sci (Lond). 1981; 61(1):75-83. DOI: 10.1042/cs0610075. View

10.

Gavras H, Biollaz J, Waeber B, Brunner H, Gavras I, Davies R . Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421". Lancet. 1981; 2(8246):543-7. DOI: 10.1016/s0140-6736(81)90937-5. View

11.

Vidt D, Bravo E, Fouad F . Drug therapy. Captopril. N Engl J Med. 1982; 306(4):214-9. DOI: 10.1056/NEJM198201283060405. View

12.

Staessen J, Lijnen P, Fagard R, Verschueren L, Amery A . Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981; 91(3):457-65. DOI: 10.1677/joe.0.0910457. View

13.

TOCCO D, DeLuna F, Duncan A, Vassil T, Ulm E . The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab Dispos. 1982; 10(1):15-9. View

14.

ONDETTI M, Cushman D . Enzymes of the renin-angiotensin system and their inhibitors. Annu Rev Biochem. 1982; 51:283-308. DOI: 10.1146/annurev.bi.51.070182.001435. View

15.

Millar J, Derkx F, McLean K, Reid J . Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol. 1982; 14(3):347-55. PMC: 1427629. DOI: 10.1111/j.1365-2125.1982.tb01990.x. View

16.

Ulm E, HICHENS M, Gomez H, Till A, Hand E, Vassil T . Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br J Clin Pharmacol. 1982; 14(3):357-62. PMC: 1427630. DOI: 10.1111/j.1365-2125.1982.tb01991.x. View

17.

Johnston C, McGrath B, Matthews P, Jackson B . Treatment of hypertension with angiotensin converting enzyme inhibitors. Clin Exp Pharmacol Physiol Suppl. 1982; 7:135-44. View

18.

Hollenberg N . Converting enzyme inhibition: implications for renal perfusion and function. Clin Exp Pharmacol Physiol Suppl. 1982; 7:73-9. View

19.

Jackson B, McGrath B, Johnston C . Correlation between angiotensin converting enzyme inhibition and the acute hypotensive response to MK 421 in essential hypertension. Clin Exp Pharmacol Physiol Suppl. 1982; 7:99-104. View

20.

Biollaz J, Brunner H, Gavras I, Waeber B, Gavras H . Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982; 4(6):966-72. View